Navigation Links
Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff

LAWRENCEVILLE, Ga. and CARDIFF, Wales, Sept. 21, 2011 /PRNewswire/ -- Genesis Biosciences, a global leader in custom fermentation, microbial product formulation and antimicrobial product development, announced today that Casey Smallwood has been promoted to vice president of operations. Additionally, Mauricio Amaya and Amit Choksi have been promoted to laboratory manager and fermentation manager, respectively, and Prasanth Maddipati joins Genesis as a new fermentation scientist. These team members will be located in Genesis' newly renovated U.S. fermentation and manufacturing facility in Lawrenceville, GA.


"Casey, Mauricio, Amit and Prasanth bring valuable experience and knowledge to the Genesis operational and technical teams, and we will look to them as we continue to develop high-quality, environmentally preferred chemical, fermentation and microbial-based solutions for our customers," stated Conrad Mielcuszny, president and chief executive officer of Genesis Biosciences.

Casey Smallwood, Vice President of Operations

Casey Smallwood brings to Genesis more than 20 years of chemical development and production management  experience in the household and institutional as well as janitorial and sanitation arenas. In his role as vice president of operations, Smallwood will oversee all manufacturing and production, customer service, telesales and equipment engineering/maintenance at Genesis. Smallwood joined Genesis Biosciences (formerly Genesis Technologies) in 2000, and he has held the positions of operations manager, production manager and customer service manager. Prior to joining Genesis, Smallwood served as operations manager at Harvard Chemical Research, a chemical manufacturer of institutional and household compounds specializing in carpet care and the primary chemical manufacturer for professional carpet systems franchises. Smallwood attended Clayton State University.

Mauricio Amaya, Laboratory Manager

Mauricio Amaya has more than 17 years of experience in formulation, research and development and regulatory experience in the microbial and specialty chemicals industries. As laboratory manager, Amaya will oversee all aspects of the Genesis' laboratory, including overall microbiological quality control for production and fermentation, chemical quality control, research and product development and customer technical support. Amaya was previously chief chemist at Genesis. Prior to joining the company, Amaya was the director of technical services at Atco International where he managed the Technical Department, which included duties such as quality control, product research and development and regulatory affairs. Amaya received a B.S. in chemistry from Oglethorpe University and an M.S. in technology management from Mercer University.

Amit Choksi, Fermentation Manager

Amit Choksi brings a breadth of laboratory and bacteria fermentation training and experience to Genesis. As fermentation manager, Choksi oversees a team of scientist and operators that manage the research, design, planning and execution of laboratory and large-scale fermentation studies of bacteria in adherence with Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Prior to joining Genesis, Choksi was a fermentation microbiologist at Merial Limited, a research-based veterinary pharmaceutical division of Merck. In this role, he designed planned and carried out laboratory studies in bacteria, developed upstream fermentation methods using bench scale and pilot scale fermentors and helped develop a new canine vaccine. Prior to that, Choksi was a scientist at Fort Dodge Animal Health, a research-based veterinary pharmaceutical division of Wyeth Pharmaceuticals, and a laboratory technician at Severn Trent Laboratory. Choksi received a B.S. in biology from The Ohio State University.

Prasanth Maddipati, Fermentation Scientist

Prasanth Maddipati joins Genesis with a solid background in bioprocess engineering, including the design and execution of microbial fermentation processes. At Genesis, he plays an important role in the monitoring and optimization of the company's fermentors and fermentation operations to help ensure accuracy and quality control. Prior to joining Genesis, Maddipati was a graduate research assistant at Oklahoma State University where he worked on fermentation of syngas to ethanol and other value-added products using a novel microbial catalyst. Maddipati has authored several publications in Bioresource Technology and has served as a panel speaker at leading biotechnology and bioengineering conferences. Maddipati received a B.Tech in industrial biotechnology from Anna University in India and an M.S. in biosystems engineering from Oklahoma State University.

Genesis Biosciences was formed in 2009 when United Kingdom-based Biotal Technologies and Lawrenceville, Georgia-based Genesis Technologies were first acquired and then merged by the CKM Group. Genesis Biosciences is a market leader in bacteria fermentation and is the first company to develop, manufacture and offer both microbial and antimicrobial products. Based on the knowledge and experience of the company's scientists and lab technicians, the company utilizes its in-house fermentation equipment and facilities to grow bacteria to the highest quality known in the marketplace. Additionally, Genesis creates solutions for the safe and natural eradication of bacteria using plant oils, essential oils and green chemistry.

About Genesis Biosciences

Genesis Biosciences is a biotechnology company specializing in bacteria fermentation, microbial, antimicrobial and environmentally preferred products and services. The company focuses its efforts on the development of diverse quality-assured products and solutions for a wide range of markets and applications. Genesis Biosciences emphasizes quality in every aspect of its business to ensure the most efficient solutions to meet customers' needs. Genesis Biosciences' U.S. facility is located in Lawrenceville, Georgia, and its European facility is in Cardiff, Wales. For more information, please visit  

SOURCE Genesis Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):